Paradox Immunotherapeutics is a biotech company focused on developing innovative monoclonal antibody treatments for protein misfolding diseases, including amyloidosis. Their proprietary immunotherapy design platform enables the selective targeting of misfolded proteins while preserving healthy proteins, addressing a significant unmet need in the market. With a strong scientific team and a proven track record in drug design, Paradox aims to provide hope for patients suffering from these debilitating conditions. The company is positioned to disrupt the notion that protein misfolding diseases are incurable, leveraging their expertise to develop transformative therapeutics that could impact as many as 30 different diseases.
Something looks off?